Valuation: Bicycle Therapeutics plc

Market Cap 25Cr 23Cr 21Cr 19Cr 36Cr 2.42TCr 36Cr 252.92Cr 100.13Cr 1.27TCr 96Cr 94Cr 4TCr P/E 2026 *
-1.4x
P/E 2027 * -1.56x
Enterprise Value -26Cr -23Cr -21Cr -19Cr -36Cr -2.45TCr -37Cr -256.15Cr -101.41Cr -1.28TCr -97Cr -95Cr -4.05TCr EV / Sales 2026 *
-14.7x
EV / Sales 2027 * -22.2x
Free-Float
71.25%
Yield 2026 *
-
Yield 2027 * -
1 day-3.43%
1 week+1.73%
Current month-4.35%
1 month-2.22%
3 months-15.38%
6 months-27.42%
Current year-50.28%
1 week 3.41
Extreme 3.41
3.8
1 month 3.33
Extreme 3.3301
4.04
Current year 3.33
Extreme 3.3301
7.34
1 year 3.33
Extreme 3.3301
9.08
3 years 3.33
Extreme 3.3301
28.67
5 years 3.33
Extreme 3.3301
62.08
10 years 3.33
Extreme 3.3301
62.08
Manager TitleAgeSince
Chief Executive Officer 57 01/09/2015
Director of Finance/CFO 46 29/01/2026
Chief Tech/Sci/R&D Officer - 01/06/2025
Director TitleAgeSince
Director/Board Member 57 01/09/2015
Director/Board Member 63 17/03/2021
Director/Board Member 69 20/02/2024
Date Insider Type Main position Quantity % Market Cap. Importance
05/10/26 Sell

Chief Operating Officer

-356 0.0009%
05/10/26 Sell

Chief Operating Officer

-406 0.0011%
05/10/26 Sell

Chief Financial Officer

-79 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
-3.43%+1.73%-54.93%-77.62% 25Cr
+2.41%-6.33%+43.43%+71.02% 6.33TCr
-0.15%+7.50%+11.01%+73.48% 5.49TCr
+0.57%+4.60%+10.07%+92.86% 5.33TCr
+0.29%+4.50%+26.83%+51.82% 4.58TCr
-1.28%+2.08%+21.51%+123.27% 4.35TCr
+0.18%+5.38%+250.92%+921.68% 4.02TCr
+0.05%+6.75%+14.48%+56.75% 3.35TCr
+1.19%-5.84%+27.86%-0.65% 2.37TCr
-0.38%+5.68%+36.43%+27.54% 2.38TCr
Average -0.06%+0.41%+38.76%+134.01% 3.82TCr
Weighted average by Cap. +0.41%+0.55%+47.48%+159.12%

Financials

2026 *2027 *
Net sales 1.75Cr 1.57Cr 1.45Cr 1.31Cr 2.45Cr 166.44Cr 2.49Cr 17Cr 6.89Cr 87Cr 6.58Cr 6.44Cr 274.93Cr 66.89L 59.73L 55.18L 50L 93.55L 63Cr 95.1L 6.64Cr 2.63Cr 33Cr 2.51Cr 2.46Cr 104.88Cr
Net income -17Cr -15Cr -14Cr -13Cr -24Cr -1.63TCr -24Cr -170.8Cr -68Cr -855.74Cr -65Cr -63Cr -2.7TCr -17Cr -16Cr -14Cr -13Cr -24Cr -1.66TCr -25Cr -173.14Cr -69Cr -867.46Cr -65Cr -64Cr -2.73TCr
Net Debt -51Cr -46Cr -42Cr -38Cr -72Cr -4.87TCr -73Cr -509.07Cr -201.55Cr -2.55TCr -192.45Cr -188.36Cr -8.04TCr -40Cr -36Cr -33Cr -30Cr -56Cr -3.83TCr -57Cr -400.42Cr -158.53Cr -2.01TCr -151.37Cr -148.16Cr -6.32TCr
Projected Income Statement - Annual - Bicycle Therapeutics plc
Logo Bicycle Therapeutics plc
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Employees
288
Date Price Change Volume
24/26/24 $3.520 -3.30% 2,57,906
22/26/22 $3.640 +1.96% 2,76,237
21/26/21 $3.570 -0.83% 4,06,403
20/26/20 $3.600 +1.84% 4,88,210
19/26/19 $3.535 +2.17% 6,92,062
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Bicycle Therapeutics plc
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
3.640USD
Average target price
9.500USD
Spread / Average Target
+160.99%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Bicycle Therapeutics plc
  1. Stock Market
  2. Stocks
  3. BCYC Stock